List view / Grid view
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
20 June 2011 | By Roche
Pivotal Phase II study with vismodegib showed positive results in people with advanced advanced basal cell carcinoma.
20 June 2011 | By Pfizer
Pfizer Inc. and Acura Pharmaceuticals Inc., announce the marketing approval from the U.S. FDA of OXECTATM (oxycodone HCl, USP) Tablets CII...
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
16 June 2011 | By Novartis
Construction of this facility represents the most significant Novartis investment in Russia...
16 June 2011 | By Sanofi
Sanofi has entered into a research collaboration with Audion Therapeutics to develop potential treatments for hearing loss...
16 June 2011 | By The Scott Partnership
Greenphire, partners with Mytrus to deliver novel and efficient web-based solutions for clinical trial patients...
16 June 2011 | By Novartis
The US FDA has accepted for review its supplemental Biologics License Application...
16 June 2011 | By Abbott
Reata and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes...
16 June 2011 | By AstraZeneca
AstraZeneca plans to establish a Predictive Science Centre in St. Petersburg...
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
15 June 2011 | By Pfizer
Pfizer Injectables, announced the addition of doxorubicin hydrochloride injection, USP...
14 June 2011 | By kdm communications limited
Technical Communities to distribute Tecan’s liquid handling platforms...
14 June 2011 | By Zyme Communications Ltd
Horizon Discovery has announced that it has successfully completed an eighteen month pilot program with Novartis...
